

CLEAN COPY OF AMENDMENTS

In the Claims:

Please cancel Claim 15.

Please amend Claim 1 as follows:

1. (Amended Once) ~~A method for treating inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising a mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to treat the inflammation.~~

Please amend Claim 2 as follows:

2. (Amended Once) ~~A method for preventing inflammation in an animal, comprising administering to the animal an effective amount of a composition comprising a mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to prevent the inflammation.~~

Please amend Claim 16 as follows:

16. (Amended Once) ~~A method for treating inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to treat the inflammation.~~

Please add new Claims 17-21:

17. (New) A method for preventing inflammation in an animal, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to prevent the inflammation.

18. (New) The method of Claim 16, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

19. (New) The method of Claim 17, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

20. (New) The method of Claim 16, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.

21. (New) The method of Claim 17, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
